A5066106914- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Acute Ischemic Stroke Management
- Venous Thromboembolism Diagnosis and Management
- Academic Writing and Publishing
- Meta-analysis and systematic reviews
- Vitamin K Research Studies
- Lipoproteins and Cardiovascular Health
- Central Venous Catheters and Hemodialysis
- scientometrics and bibliometrics research
- Ferrocene Chemistry and Applications
- Mast cells and histamine
- Cerebrovascular and Carotid Artery Diseases
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Computational Drug Discovery Methods
- Infective Endocarditis Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Aortic aneurysm repair treatments
- Cardiac and Coronary Surgery Techniques
- Cardiac Valve Diseases and Treatments
University of Catania
2022-2025
Policlinico Universitario di Catania
2022-2025
The evolution of anticoagulation therapy, from vitamin K antagonists to the advent direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk absence therapeutic indications specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a contributor intraluminal thrombus formation growth, playing...
Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual [DAPT] or pathway inhibition [DPI]) are recommended for secondary prevention in patients who underwent percutaneous coronary intervention (PCI) after initial DAPT. We aimed to characterize eligibility such strategies explore what extent guidelines applied clinical practice. Patients PCI acute chronic syndrome completed DAPT were analyzed from a prospective registry. categorized into SAPT, prolonged...
Background – Although Factor XI (FXI) inhibitors are currently tested for the prevention of thrombotic events, their early treatment could prevent thrombus consolidation in ST-segment elevation myocardial infarction (STEMI). This study aims to characterize coagulation FXI levels and variations patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Methods Patients were prospectively enrolled between December 2023 May 2024. activity (FXIa) measured at admission after...
Randomized trials are often presented at medical conferences and published simultaneously or later. Predictors of simultaneous publication its consequences undetermined. Our aim was to characterize the practice publication, identify predictors, evaluate impact.
Introduction and objectives: Randomized trials are often presented at medical conferences published simultaneously or later. Predictors of simultaneous publication its consequences undetermined. Our aim was to characterize the practice publication, identify predictors, evaluate impact. Methods: In this cross-sectional study, we included randomized late-breaking science sessions major cardiovascular from 2015 2021. The association trial characteristics with timing analyzed. impact vs...
Abstract Background ST-segment elevation myocardial infarction (STEMI) is characterized by a significant thrombotic burden, where the coagulation cascade, including Factor XI (FXI) activity, plays crucial role. In STEMI and other conditions, FXI levels vary according to patient characteristics timing from event. Understanding changes in activity may offer valuable insights into optimal selection for use of investigational inhibitors. Purpose Our aim was characterize variations patients....